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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and structurally similar halogenated aromatic hydro-
carbons cause a broad range of immunologic effects in experimental animals including decreased
host resistance to infectious disease and suppressed humoral and cell-mediated immune
responses. In the mouse, TCDD immunotoxicity has been shown to be an aryl hydrocarbon (Ah)
receptor-dependent process. However, despite considerable research, the biochemical and
molecular alterations that occur subsequent to Ah receptor activation that lead to altered immune
reactivity remain to be elucidated. In addition to immune suppression, TCDD promotes inflamma-
tory responses. This effect may result from an upregulation of the production of inflammatory
cytokines such as interleukin-1 and tumor necrosis factor. Nonhuman primates exposed to TCDD
show suppressed antibody responses and changes in lymphocyte subsets in the peripheral blood.
The immunotoxic effects of TCDD in humans are poorly characterized, and few studies have
examined the immune status of individuals with known, documented exposure to TCDD. It is
important for laboratory research to focus on defining TCDD-sensitive immunologic biomarkers in
animal models that can also be used in human subjects. Understanding the mechanisms that
underlie species differences in TCDD immunotoxicity is also of critical importance for extrapolation
of effects seen in laboratory animals to man. Environ Health Perspect 103(Suppl 9):47-53 (1995)
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Introduction
2,3,7,8-Tetrachlorodibenzo-p -dioxin
(TCDD) has posed much concern to both
the public and the scientific community
because ofits toxic potency and widespread
distribution in the environment. TCDD is
the most toxic member of a large class of
planar halogenated aromatic hydrocarbons
(HAH) that include other environmental
contaminants such as polychlorinated
biphenyls (PCBs) and dibenzofurans
(PCDFs). These chemicals are unusual in
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that most oftheir toxicity is elicited through
their initial binding to a specific intracellular
protein, the aryl hydrocarbon (Ah) receptor
(AhR) (1,2). In a process similar to steroid
hormone receptor-mediated responses, the
receptor-ligand complex is translocated
from the cytoplasm to the nucleus where it
binds to DNA at specific sequences called
dioxin-response elements (DREs) to modify
transcription ofthe DRE-containing genes
(3,4). A widely held hypothesis is that
altered transcription leads to over produc-
tion or underproduction ofspecific protein
products that mediate the ultimate bio-
chemical and toxic effects ofTCDD and
related HAH. In support of the AhR
hypothesis, differences in toxic potency
between various chlorinated congeners of
dioxins, furans, and biphenyls generally cor-
relate well with differences in their binding
affinity for theAh receptor (5).
Immunotoxicity Studies
LaboratoryAnimalStudies
The immune system appears to be one of
the most sensitive targets for the toxicity
of TCDD and related HAH. Studies in
the 1970s demonstrated that exposure of
laboratory rodents to low doses ofTCDD
by diet or by gavage resulted in involution
of the thymus, increased susceptibility to
various infectious diseases, and suppression
ofboth cell-mediated and humoral immune
functions (6,7). Subsequently, many differ-
ent animal models in addition to rodents
have been used to demonstrate the immuno-
toxicity ofTCDD. Unfortunately, due to
differences in experimental design and out-
comes, a defined TCDD-induced immune
deficiency syndrome has not emerged.
Likewise, because ofthe difficulties associ-
ated with the measurement of many
immune functions in some species ofani-
mals, there is no clear ranking ofspecies sen-
sitivity to TCDD immunotoxicity.
The type of immune response that is
most sensitive to suppression following
TCDD exposure is also difficult to general-
ize from animal studies. For example, the
antibody response to sheep red blood cells
(SRBC) in C57B1/6 mice is very sensitive
to suppression by TCDD, with a single
dose ofTCDD of 0.7 pg/kg sufficient to
suppress this response to 50% of the con-
trol level (8-10). In contrast, a dose of
TCDD as high as 30 pg/kg does not sup-
press this response in rats (11). However,
even in mice, antibody responses to differ-
ent antigens may differ more than 10-fold
in sensitivity to suppression by TCDD as
compared to the response to SRBC (8,9),
which indicates that the nature ofthe anti-
genic stimulus is also an important factor.
This is not unexpected given that different
types of antigens are known to evoke dif-
ferent cellular interactions (e.g., antigen-
presenting cells for soluble vs particulate
antigens, requirement for different T-helper
cell subtypes for humoral and cell-mediated
responses, sensitivity to suppressor T-cell
regulation, etc.). Understanding the mecha-
nism(s) ofTCDD toxicity to these different
subsets of cells of the immune system will
be necessary for understanding why certain
immune responses are more sensitive to
TCDD than others.
Involution ofthe thymus gland follow-
ing TCDD exposure is a hallmark of
TCDD toxicity in several animal species
(2,12); however, no direct relationship
between the effects ofTCDD on the thy-
mus and effects on immune function have
been demonstrated following exposure of
animals to TCDD (13,14). In adult ani-
mals, immune suppression occurs at doses
ofTCDD below that required for thymic
atrophy (15-17), suggesting that thymus
toxicity and systemic immune toxicity are
independent. On the other hand, the effects
ofprenatal exposure to TCDD on the fetal
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thymus gland could have serious and long-
lasting consequences in terms ofimmune
function since the thymus gland is critical
for the selection ofT cells that can appro-
priately discriminate between selfand non-
self molecules (18). Several studies suggest
that prenatal exposure of mice or rats to
TCDD is more immunosuppressive than
comparable exposure of adults (19-23).
However, the specific role ofthe thymus in
mediating such prenatal effects on immune
function has not been determined, and the
effects ofprenatal TCDD exposure on T-
cell selection have not been examined. On
the other hand, it was recently reported that
recovery from a thymotoxic dose ofTCDD
did not affect intrathymic negative selection
ofpotentially autoreactive VP6+ T cells in
adult Mls_1a mice (24).
Like other toxic responses to TCDD,
the effects ofTCDD on the immune sys-
tem appear to be dependent on the AhR.
Two lines ofevidence support this conclu-
sion: comparative studies using PCDD,
PCDF, and PCB congeners show that
potency to cause immune suppression cor-
relates with the binding affinity for the
AhR (25-29); and studies using mice with
a defined Ah genotype show that mice with
high affinityAhR (e.g., Ahbb C57BI/6 mice)
are more sensitive to immune suppression
by these compounds than mice with lower
affinity AhR (e.g., Ahdd DBA/2 mice or
Ahdd congenic C57BI/6 mice)(8,25,26,29).
AhR-dependent responses include suppres-
sion of the T-cell-dependent antibody
response to SRBC (8,25-28,30,31), sup-
pression ofthe T-cell-independent antibody
response to trinitrophenyl-lipopolysaccha-
ride (8), suppression of the cytotoxic T
lymphocyte (CTL) response to allogeneic
tumor cells (29,32) bone marrow toxicity
(33), and suppression of the cytotoxic
responses of activated neutrophils (34).
However, while the data relating HAH
immunotoxicity to AhR-dependent events
are convincing, it should be emphasized
that all ofthe data have been obtained from
studies in inbred mice using an acute or
subacute exposure regimen. Except for
thymic atrophy, structure-immunotoxicity
relationships in other species including rats
have not been established, and other
species with defined Ah genotype are not
currently available.
It is generally accepted that there are
multiple cellular targets within the
immune system that can be altered by
TCDD since both T-cell-mediated and
antibody-mediated immune responses are
suppressed following TCDD exposure;
however, the specific cellular defects
induced by TCDD have not been fully
elucidated despite considerable research.
One ofthe problems has been a difficulty
in demonstrating direct effects ofTCDD
on in vitro responses of lymphoid cells
(35,36). This is especially true with T
cells; direct effects ofTCDD on T cells in
vitro have not been observed even though
T-cell functions in vivo are clearly altered by
TCDD (14,32,33,36-38). Furthermore,
when in vitroeffects ofTCDD are observed,
they may be inconsistent with the in vivo
immunotoxic effects ofTCDD. For exam-
ple, in vitro suppression of the antibody
response to SRBC has been reported by
some laboratories to be independent ofthe
AhR (39,40), whereas suppression of this
response in vivo is clearly AhR-dependent.
Although the basis for the discrepancies
between in vivo and in vitro effects is not
known, differences in culture conditions
may be partially responsible since the in
vitro effects ofTCDD on lymphoid cells
appear to be influenced by unknown fac-
tors present in serum-supplemented tissue
culture media (41,42). Interestingly,
serum was also shown to modulate the
induction of P4501AI-dependent enzyme
activity by TCDD in primary cultures of
hepatocytes (42), demonstrating that the
serum phenomenon is not restricted to
effects on lymphocytes.
While T-cell responses appear to be
resistant to direct effects ofTCDD, several
laboratories have reported that TCDD
directly alters B-lymphocyte functions in
vitro (13,40,43,44). Studies using both
murine and human B cells suggest that
TCDD alters the terminal differentiation
of B cells into antibody-secreting plasma
cells without altering B-cell proliferation
(43-45). The induction ofprotein kinase
activity (46-48) and altered calcium
homeostasis (49) have been implicated in
the immunotoxic effects ofTCDD on B
cells. Snyder et al. (48) reported that
TCDD induced the phosphorylation of
29, 45, 52, and 63 kDa proteins in B cells,
which by density gradient were character-
ized as activated B cells. Interferon-y
(IFNy) was shown to antagonize the
TCDD-induced phosphorylation and to
reverse the TCDD-induced suppression of
the antibody response to SRBC in vitro.
Interestingly, suppression ofIFNy produc-
tion has recently been correlated with the in
vivo suppression ofcytotoxic T-lymphocyte
activity in TCDD- and PCB-treated mice
[NI Kerkvliet, unpublished data; (50)].
Thus, changes in IFNy production may
represent an underlying mechanism for
TCDD-induced immunotoxicity.
Activities associated with innate immune
function have also been examined following
TCDD exposure and have generally been
found to be resistant to suppression when
assessed ex vivo. Macrophage-mediated
phagocytosis, macrophage-mediated tumor
cell cytolysis or cytostasis, oxidative reactions
ofneutrophils and macrophages, and nat-
ural killer (NK) cell activity were not sup-
pressed following TCDD exposure, with
doses as high as 30 pg/kg failing to suppress
NK and macrophage functions (51,52). A
potentially important exception is the
reported inhibition ofphorbol ester-acti-
vated antitumor activity ofneutrophils by
TCDD (34). On the other hand, the
pathology associated with TCDD toxicity
often includes neutrophilia and an
inflammatory response in certain tissues
(e.g., liver and skin) characterized by acti-
vated macrophage and neutrophil accumu-
lation (53-55). While these observations
may simply reflect a normal inflammatory
response to tissue injury, there is increasing
experimental evidence to suggest that
inflammatory cells may be activated by
TCDD exposure. For example, TCDD
exposure has been shown to produce an
enhanced inflammatory response in the
peritoneal cavity of mice following SRBC
injection (56). This effect ofTCDD was
characterized by a 2- to 4-fold increase in
the number ofneutrophils and macrophages
locally infiltrating the intraperitoneal site of
SRBC injection. However, the time course
of the cellular influx was not altered by
TCDD exposure. Likewise, the expression
ofactivation markers (I-A and F4/80) and
the antigen-presenting function ofthe peri-
toneal exudate cells was unaltered byTCDD
exposure. Thus, the effect of TCDD
appeared to reflect a quantitative rather than
a qualitative change in the inflammatory
response. Interestingly, although enhanced
antigen clearance/degradation caused by the
increased numbers ofphagocytic cells could
result in a decreased antibody response in
TCDD-treated mice, increasing the amount
of antigen used for sensitization did not
alter the immunosuppressive effect of
TCDD (56). Thus, a relationship between
the inflammatory and immunosuppressive
effects ofTCDD in the SRBC model was
not apparent.
One mechanism bywhich TCDD could
augment inflammatory responses is through
enhanced production of inflammatory
mediators. For example, recent evidence
suggests that the hypersusceptibility of
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TCDD- and PCB-treated animals to
endotoxin (57,58) and the increased
inflammatory response to SRBC (59) may
be related to an increased production of
tumor necrosis factor (TNF). The ability of
methylprednisolone to reverse the mortality
associated with TCDD/endotoxin treatment
is also consistent with an proinflammatory
mechanism (60). Similarly, increased
inflammatory mediator production may
underlie the enhanced rat paw edema
response to carrageenan and dextran in
TCDD-treated rats (61,62). A primary
effect ofTCDD on inflammatory mediator
production is supported by the recent
findings that keratinocytes exposed to
TCDD in vitro have increased mRNA for
interleukin-1p, plasminogen activator
inhibitor-2, and transforming growth factor
a and decreased mRNA for transforming
growth factor 02 (63,64). Interestingly,
mRNA for TNF was not altered by TCDD
treatment (64). The effects ofTCDD on
keratinocytes are similar to the effects of
TCDD on the macrophage cell line IC-21
in that TCDD treatment increased endo-
toxin induction ofmRNA for interleukin-1
but notTNF (65).
The influence ofTCDD exposure on
inflammatory mediator production and
action is an important area for further
study. In this regard, it is relevant to note
that treatment ofmice with a soluble TNF-
binding protein, under conditions that
resolved the hyperinflammatory response to
SRBC induced by TCDD exposure, did
not affect TCDD-induced suppression of
the anti-SRBC antibody response (66).
Similarly, daily treatment of mice with
aminoguanidine, an inhibitor ofinducible
nitric oxide synthase, did not influence the
suppression of the anti-SRBC antibody
response by TCDD (66). Thus, the rela-
tionships, ifany, between the proinflam-
matory and immunosuppressive effects of
TCDD remain to be elucidated.
The ability of TCDD to augment
the production of certain inflammatory
chemoattractive mediators suggests that
TCDD exposure could result in enhanced
host resistance to pathogenic infection since
the rapid influx ofphagocytes to the site of
pathogen invasion is an important factor in
host resistance. However, since TCDD
exposure is at the same time immunosup-
pressive, which results in decreased specific
immune responses generated by T and B
lymphocytes, the overall impact ofTCDD
exposure on disease susceptibility will
probably vary depending on the nature of
the pathogen and on the major mode ofhost
response to the specific infectious agent.
These divergent effects ofTCDD on inflam-
mation and immunity may, in fact, help to
explain the disparate effects ofTCDD in dif-
ferent host resistance models that have been
previously reported (20,52,67,68).
Studies inNonhuman Primates
A limited number ofstudies using nonhu-
man primates have been conducted to
assess TCDD immunotoxicity. Few
immunologic effects were found in rhesus
monkeys and their offspring that were
chronically exposed to TCDD in food at
levels of5 or 25 parts per trillion (ppt) for
4 years (69). Although T-cell numbers
decreased in the TCDD-fed mothers (with
a selective decrease in CD4+ cells), T-cell
function as measured by proliferation to
mitogens, alloantigens, or xenoantigens
was not affected. NK cell activity and the
antibody response to tetanus toxoid were
also normal. Interestingly in the offspring,
T-cell numbers were increased as was the
antibody response to tetanus toxoid. [It is
relevant to note that the antibody response
to SRBC was not measured in these stud-
ies because the antibody response to SRBC
but not to tetanus toxoid was decreased in
monkeys exposed to much higher levels of
PCB (70)].
In other studies, a single injection of
TCDD in marmosets (Callithrixjacchus)
resulted in a decrease in the percentages of
CD20+ B cells and CD4+ T cells and an
increase in the percentage ofCD8+ T cells
in the blood without affecting the total
numbers ofthese cells (71). The CD4+ sub-
set that was most affected was the CDo29+
helper-inducer or memory subset, with sig-
nificant effects observed after a TCDD dose
of 10 ng/kg but not after a dose of3 ng/kg.
The changes in the T-cell subsets were
intensified following culture of the cells
with mitogens (72). Paradoxically, how-
ever, chronic exposure ofyoung marmosets
to lower levels ofTCDD (0.3 ng/kg/week
for 24 weeks) produced the opposite effect
of acute exposure on the CD4+CDw29+
subset, with TCDD treatment resulting in
a significant increase in this population
(73). Upon transfer of the animals to a
higher dose ofTCDD (1.5 ng/kg/week) for
3 weeks, the enhancing effect was reversed
and suppression ofthe CD4+CDw029+ sub-
set was observed. After discontinuation of
dosing, the reduction in the percentage and
absolute number ofCD4+CDw029+ cells
persisted for 5 weeks, reaching normal range
7 weeks later. Based on these results the
authors concluded that "extrapolations of
the results obtained at higher doses to very
low exposures is not justified with respect
to the effects induced by TCDD on the
immune system of marmosets" (73). The
relevance ofthese changes in subset distrib-
utions to immune function in the marmoset
have not been determined. Interestingly, a
similar reduction in the "memory" CD4+ T
cell subset was observed in C57B1/6 mice
treated once a week for 60 weeks with 0.2
pg/kg TCDD (74), suggesting that the
memory CD4+ T cell may represent a very
sensitive biomarker ofexposure to TCDD.
A reduction in the memory T-cell popula-
tion is consistent with the immunosuppres-
sive effects ofTCDD.
HumanStudies
The immunotoxicity ofTCDD in humans
has been the subject ofa limited number of
studies in which cohorts were exposed to
TCDD either occupationally or as a result
of residence in a TCDD-contaminated
area. Mocarelli et al. (75) reported on the
immune status of44 children, 20 ofwhom
had chloracne, that were exposed to TCDD
following an explosion at a herbicide fac-
tory in Seveso, Italy. No abnormalities
were found in serum immunoglobulin con-
centrations, levels ofcirculating comple-
ment, or lymphoproliferative responses to
T- and B-cell mitogens. Interestingly, in a
study conducted 6 years after the explo-
sion, a different cohort ofTCDD-exposed
children exhibited a significant increase in
complement protein levels, which corre-
lated with the incidence ofchloracne, as
well as increased numbers of peripheral
blood lymphocytes and increased lympho-
proliferative responses (76). No specific
health problems were correlated with
dioxin exposure in these children.
Webb et al. (77) reported the findings
from immunologic assessment of41 per-
sons from Missouri with documented adi-
pose tissue levels ofTCDD resulting from
occupational, recreational, or residential
exposure. Ofthe participants, 16 had tissue
TCDD levels less than 20 ppt, 13 had lev-
els between 20 and 60 ppt, and 12 had lev-
els greater than 60 ppt. The highest level
was 750 ppt. Data were analyzed by multi-
ple regression based on adipose tissue level
and the clinical-dependent variable.
Increased TCDD levels were correlated
with an increased percentage and total
number ofT lymphocytes. CD8+ and Ti 1+
T cells accounted for the increase, while
CD4+ T cells were not altered in percent or
number. Lymphoproliferative responses to
T-cell mitogens or tetanus toxoid were not
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altered nor was the cytotoxic T-cell response.
Serum immunoglobulin A (IgA) was
increased but IgG was not. No adverse clin-
ical disease was associated with these
TCDD levels in these subjects. Only 2 of
the 41 subjects reported a history ofchlo-
racne. These findings differ from those
reported for the Quail Run Mobile Home
Park residents (tissue levels unknown) in
which decreased T-cell numbers (T3+,
CD4+, and T 1+) and suppressed cell-
mediated immunity was reported (78).
However, subsequent retesting of these
anergic subjects failed to confirm the sup-
pressed immunity (79). On the other hand,
when sera from some ofthese individuals
were tested for levels ofthe thymic peptide
thymosin a-1, the entire frequency distrib-
ution for the TCDD-exposed group was
shifted toward lower thymosin a-i levels
(80). A statistically significant difference
between the TCDD-exposed persons and
controls remained after controlling for age,
sex, and socioeconomic status, with a trend
of decreasing thymosin a-I levels as the
number of years of residence in the
TCDD-contaminated residential area
increased. The thymosin a-I levels were
not correlated with changes in other
immune system parameters or with any
increased incidence ofclinically diagnosed
immune suppression. The decrease in thy-
mosin a-I levels in this cohort contrasts
with the increase in thymosin a-I seen in
PCB-treated monkeys (81).
Two studies have evaluated the
immunologic function ofVietnam veterans
exposed to TCDD via use ofthe pesticide
Agent Orange. When U.S. Army ground
troops were matched with a comparison
population, no differences in lymphocyte
subsets or serum immunoglobulins were
found (82). In the U.S. Air Force Ranch
Hand Study, comprehensive immunologic
profiles were developed for each participant
and correlated with serum TCDD concen-
trations (83). The only significant positive
association with TCDD exposure was
increased serum IgA level. Roegner et al.
(83) suggested that the increase in serum
IgAwas consistent with a subclinical inflam-
matory response, but no other evidence for
an inflammatory response was obtained.
The basis for the lack ofconsistent or
significant exposure-related effects to
TCDD in these human populations is
unknown and may be dependent on several
factors. Most notable in this regard is the
inherent difficulties in assessing subclinical
immunomodulation in an outbred human
population. Most immunologic assays have
avery broad range ofnormal responses that
reduce the sensitivity to detect small
changes. Similarly, the assays used to exam-
ine immune function in humans exposed
to TCDD have unfortunately been based
to a greater extent on what was clinically
feasible (e.g., lymphocyte phenotype, mito-
gen responsiveness) rather than on assays
that have been shown to be sensitive to
TCDD in animal studies (e.g., antibody
response to SRBC). Thus, the lack ofcon-
sistent or significant immunotoxic effects in
humans resulting from TCDD exposure
may be as much a function of the assays
used as the immune status ofthe cohort. In
addition, few studies have examined the
immune status ofindividuals with known,
documented exposure to TCDD. Rather,
cohorts based on presumption ofexposure
have been studied. There is some evidence
to suggest that the lack ofconsistent, signi-
ficant effects may sometimes be due to the
inclusion ofsubjects that had little or no
actual exposure to TCDD (77). Likewise,
the important role that Ah phenotype plays
in TCDD immunotoxicity has not been
considered when addressing human sensi-
tivity. Finally, in most studies, the assess-
ment of immune function in exposed
populations was carried out long after expo-
sure to TCDD ceased. Thus, recovery from
any immunotoxic effects of TCDD may
have occurred by the time oftesting.
As an alternate approach to evaluating
the sensitivity of the human immune sys-
tem to TCDD, several laboratories have
recently reported on the direct in vitro
effects ofTCDD on human lymphocytes.
Neubert et al. (72) reported that TCDD
reduced the percentage of CD20+ B cells
and CD4+CDo29+ T cells in pokeweed
mitogen-stimulated cultures of peripheral
blood lymphocytes at concentrations as
low as 10-12 to 10-14 M TCDD. These
results, however, were not corroborated in
similar studies reported by Lang et al. (35)
in which concentrations ofTCDD ranging
from 10-7 to 10-11 M were tested. In
another model, Wood and Holsapple (84)
reported that proliferation and antibody
secretion by pokeweed mitogen-stimulated
human tonsillar lymphocytes were not
altered by exposure to TCDD at concen-
trations ranging from 3x 10-8 to 10-io M.
Yet these same concentrations ofTCDD
significantly suppressed the ability of
human tonsillar B cells ofsome donors to
produce antibodies in response to toxic
shock syndrome toxin (85). Because ofthe
limited amount of data available and the
lack ofcorroboration between laboratories,
no conclusions can yet be drawn regarding
the relative sensitivity ofhuman lymphoid
cells to TCDD.
Research Needs
For the field of immunotoxicology in
general, there is a strong need to establish a
broad database ofnormal values for the clin-
ical immunology end points that may be of
use as biomarkers ofimmune function in
immunotoxicity assessments. To validate
these biomarkers, there is a parallel need for
animal research to identify TCDD-sensitive
immune end points in animals that can also
be measured in humans in order to establish
correlative changes in the biomarker and
immune function. In particular, it will be
important to determine in animal models
how well changes in immune function in
the lymphoid organs (e.g., spleen, lymph
nodes) correlate with changes in the expres-
sion oflymphocyte subset/activation mark-
ers in peripheral blood. Also limited at the
present time are good correlative data
between changes in immune function mea-
surements and changes in host resistance to
specific disease challenges induced by xeno-
biotic exposure. Until such correlations are
established, the interpretation ofchanges
observed in subsets/activation markers in
human peripheral blood lymphocytes in
terms ofhealth risk will be limited to specu-
lation. Research must also continue to
develop and characterize immune models
using multiple animal species that will lead
to an understanding of the underlying
mechanisms of HAH immunotoxicity. For
example, there is a clear need to document
Ah receptor involvement in the immuno-
toxicity of TCDD and related HAH in
species other than mice. These studies need
to go beyond descriptive immunotoxicity
assessment to determine the mechanistic
basis for differences in species sensitivity to
TCDD immunotoxicity following both
acute and chronic exposure. Until then, risk
assessment must be based on the best avail-
able data derived from well-controlled ani-
mal studies on TCDD immunotoxicity.
Because the antibody response to SRBC has
been widely studied and has been shown to
be dose-dependently suppressed by TCDD
and related HAH in several animal species,
including nonhuman primates, this data-
base would appear to be best suited for cur-
rent application to risk assessment. The
approaches used to establish acceptable
exposure levels for humans for immuntoxic-
ity should be based on the same procedures
that are used for other noncarcinogenic
toxic endpoints.
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